Kedem Pharmaceuticals initiates development of sublingual cancer drug
Gleevec is for the treatment of several blood related cancers
Kedem Pharmaceuticals, a developer of specialist pharmaceuticals with a focus on sublingual drug delivery systems, has started to develop Gleevec (imatinib), a drug for the treatment of several blood related cancers in children and adults.
In children the drug has demonstrated a powerful action against Chronic Myeloid Leukemia. The drug is administered orally and in children there is a significant issue in getting the drug swallowed, due to size of the pill and bad taste.
The firm says its sublingual formulation with taste masking features makes the drug acceptable and pleasant in taste for the children with chronic dosage requirements.
Kedem Pharmaceuticals has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, painkillers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies.
